GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (LSE:BVXP) » Definitions » Short-Term Debt

Bioventix (LSE:BVXP) Short-Term Debt : £0.00 Mil (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bioventix Short-Term Debt?

Bioventix's Short-Term Debt for the quarter that ended in Jun. 2024 was £0.00 Mil.


Bioventix Short-Term Debt Historical Data

The historical data trend for Bioventix's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventix Short-Term Debt Chart

Bioventix Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioventix Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bioventix Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Bioventix Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Bioventix's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioventix Business Description

Traded in Other Exchanges
Address
27–28 Eastcastle Street, London, GBR, W1W 8DH
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.

Bioventix Headlines

No Headlines